Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/011465METHOD FOR VACCINATING AVIANS AGAINST REOVIRUS
WO 21.01.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2020/041793 Applicant BIOMUNE COMPANY Inventor DORSEY, Kristi, Mae
The present invention relates to a method vaccinating avian against reovirus.
2.WO/2021/011368TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNASE) ACTIVITY
WO 21.01.2021
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
Appl.No PCT/US2020/041579 Applicant GENKIN, Dmitry Dmitrievich Inventor GENKIN, Dmitry Dmitrievich
The invention relates to the nervous system-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of microbial and viral cell free DNA (cfDNA) accumulated in cerebrospinal fluid (CSF), brain and other parts of nervous system, with the use of such nervous-system specific delivery and/or expression for treatment of various diseases associated with protein misfolding.
3.WO/2021/008501ENGINEERED VACCINIA VIRUS
WO 21.01.2021
Int.Class A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
Appl.No PCT/CN2020/101727 Applicant SHENZHEN HUA YAO KANG MING BIOPHARMACEUTICAL CO., LTD. Inventor YUAN, Ming
An engineered vaccinia virus, a pharmaceutical composition containing the same, and methods for use in treating a subject in need using the same are provided. The engineered vaccinia virus includes a mutated viral sequence and a heterologous sequence. The mutated viral sequence is used for selective replication in tumor cells and/or activation of immune cells. The heterologous sequence encodes an immune co-stimulatory pathway activating molecule, immunomodulator gene, a truncated viral envelope gene, and/or a tumor suppressor. The heterologous sequence is stably incorporated into the genome of the engineered vaccinia virus. The pharmaceutical composition includes an effective amount of the engineered vaccinia virus and a pharmaceutical acceptable vehicle. The methods for use in treating the subject in need include administering the engineered vaccinia virus to the subject.
4.WO/2021/011544HIV VACCINES AND METHODS OF MAKING AND USING
WO 21.01.2021
Int.Class A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
Appl.No PCT/US2020/041945 Applicant GILEAD SCIENCES, INC. Inventor LIU, Xinan
Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.
5.WO/2021/011619SENECAVIRUS A VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM
WO 21.01.2021
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2020/042083 Applicant SOUTH DAKOTA BOARD OF REGENTS Inventor DIEL, Diego G.
The present invention is directed to novel nucleotide sequences of Senecavirus A ("SVA"), including novel genotypes thereof, which are useful as live attenuated and other vaccine compositions for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine SVA genotypes and isolates. Diagnostic and therapeutic sequences are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length SVA genomes that can replicate efficiently in host animals and tissue culture.
6.WO/2021/004561RUBELLA VIRUS SPIKE CONSTRUCT
WO 14.01.2021
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/DE2020/000024 Applicant INSTITUT VIRION-SERION GMBH WÜRZBURG Inventor SCHUMACHER, Thomas
The Rubella virus spike construct comprises at least an E1 component and an E2 component that are interlinked. The E1 component consists of the E1 envelope protein whose C terminal transmembrane region and intravirion domain have been removed and whose N terminus comprises the ectodomain of the E1 envelope protein. The E2 component consists of the E2 envelope protein whose transmembrane regions and intravirion domain have been removed and whose C terminus comprises the ectodomain of the E2 envelope protein. The C terminus of the E2 component is linked by direct fusion or by means of a linker so that an E1-E2 fusion protein is obtained.
7.WO/2021/007070CHIMERIC ANTIGENS FOR TREATING VIRAL INFECTION
WO 14.01.2021
Int.Class A61K 39/29
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
29Hepatitis virus
Appl.No PCT/US2020/040272 Applicant AKSHAYA BIO INC. Inventor SHI, Yuenian
Disclosed herein are chimeric antigens and used of there of in combination with antiviral agents to elicit immune responses against chronic Hepatitis B infections, thus breaking tolerance to hepatitis B virus in the host.
8.WO/2021/005338NOVEL CANCER ANTIGENS AND METHODS
WO 14.01.2021
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/GB2020/051592 Applicant THE FRANCIS CRICK INSTITUTE LIMITED Inventor KASSIOTIS, George
There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.
9.WO/2021/007572METHODS FOR GROWING AFRICAN SWINE FEVER VIRUS IN FETAL PORCINE LUNG ALVEOLAR MACROPHAGE CELLS
WO 14.01.2021
Int.Class A61K 39/187
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
187Hog cholera virus
Appl.No PCT/US2020/041762 Applicant APTIMMUNE BIOLOGICS, INC. Inventor ZUCKERMANN, Federico, A.
A method for generating progeny of an African swine fever (ASF) virus includes providing an isolated or purified fetal porcine lung alveolar macrophage cell capable of replicating the ASF virus, wherein the cell is cultured for at least 5 passages; exposing the cell to the ASF virus; and allowing the ASF virus to replicate in the cell; thereby generating progeny of the ASF virus.
10.WO/2021/004389PROTEOLYTIC TARGETED VIRUS, LIVE VACCINE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF
WO 14.01.2021
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2020/100086 Applicant SI, Longlong Inventor SI, Longlong
Provided is a proteolytic targeted virus. One or more proteolytic targeted molecules that may be recognized by an ubiquitin-proteasome system are contained at the site of one or more different proteins, and viral protein is connected to the proteolytic targeted molecules by means of one or more linking chains that may be selectively cleaved. Also provided are a nucleic acid molecule encoding the proteolytic targeted virus, a nucleic acid vector expressing the proteolytic targeted virus, a preparation method for the proteolytic targeted virus, the preparation of attenuated live viruses, the replication of non-viable viruses, the replication of controllable viable viruses, and methods for preparing vaccines and drugs related to uses for preventing and treating virus infections, a vaccine or a pharmaceutical composition comprising the proteolytic targeted virus, and a system for preparing the proteolytic targeted virus.